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Gordon A. Ewy, MDF or nearly a half-century, guidelines have rec-ommended epinephrine (adrenaline) as anessential adjunct to resuscitation of patients
with cardiac arrest. However, the report by Dumas
et al. (1) in this issue of the Journal is one of a growing
number of papers questioning the role of this vaso-
pressor in the management of patients with out-of-
hospital cardiac arrest (OHCA) (1).SEE PAGE 2360TIME-SENSITIVE ROLE OF VASOPRESSORS
DURING RESUSCITATION
Vasopressors have an essential but time-sensitive
role in improving return of spontaneous circulation
(ROSC) and neurologically intact survival in studies of
ventricular ﬁbrillation (VF) arrest. Insight into their
role is perhaps best appreciated in the context of
Weisfeldt and Becker’s (2) “3-phase time-sensitive
model” of VF. In this model, during the ﬁrst few mi-
nutes, called the “electrical” phase, all that is needed
is prompt deﬁbrillation. This is why implantable
cardioverter-deﬁbrillators and automated external
deﬁbrillators are effective. The initial phase of VF
arrest may be prolonged by early and near continuous
chest compressions, as ﬁrst reported a half-century
ago by Kouwenhoven et al. (3).
Patients deﬁbrillated during this preliminary phase
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Thus, any comparison of survival between patients
with OHCA treated by emergency medical service
personnel who do or do not receive epinephrine
during the electrical phase will most likely favor
those who do not receive epinephrine.
In contrast, during the second or “circulatory”
phase of VF, vasopressors are often necessary to
augment the coronary perfusion pressure (CPP)
generated by chest compressions to increase the
chance of obtaining ROSC (4–6). It should not need
emphasis, but without ROSC there is no survival.
During the third or “metabolic” phase of VF arrest,
survival is rare. Even restoration of optimal CPP
is unlikely to result in survival (7). Very late in car-
diac arrest, those who attain ROSC without epi-
nephrine obviously have a better pathophysiological
condition than those who require epinephrine for
ROSC; therefore, in the absence of a randomized trial,
comparing survival of those who did and did not
receive epinephrine after 20 min of cardiac arrest is
not helpful. This fact, long known from animal
research, is becoming of concern in humans, perhaps
accounting for the increasing number of reports
questioning the role of epinephrine in managing
OHCA.
Dumas et al. (1) also found the effects of
epinephrine during resuscitation efforts of OHCA to
be time sensitive. When epinephrine was given
within the ﬁrst 9 min after cardiac arrest, patients
had a better outcome (adjusted odds ratio [aOR]:
0.54; 95% conﬁdence interval [CI]: 0.32 to 0.91)
compared with those who received treatment be-
tween 10 and 15 min (aOR: 0.33; 95% CI: 0.20 to
0.56), between 16 and 22 min (aOR: 0.23; 95% CI: 0.12
to 0.43), and >22 min after cardiac arrest (aOR: 0.17;
95% CI: 0.09 to 0.34).
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2369RANDOMIZED CONTROLLED TRIAL
IN HUMANS
The ﬁrst and, to date, only reported randomized,
double-blind, placebo-controlled trial of adrenaline
(epinephrine) in patients with OHCA by Jacobs et al.
(8) showed that ROSC occurred in 8.4% of patients
receiving placebo versus 23.5% receiving adrenaline
(odds ratio: 3.4; 95% CI: 2.0 to 5.6) (8). Survival to
hospital discharge was 1.9% and 4.0% for those who
received placebo or adrenaline, respectively (odds
ratio: 2.2; 95% CI: 0.7 to 6.3). All but 2 patients (both
in the adrenaline group) had a Cerebral Performance
Category score of 1 to 2. However, in this study,
patients receiving adrenaline had no statistically
signiﬁcant improvement in survival to hospital
discharge. Unfortunately, in this important study,
time to administration of adrenaline was not re-
ported. However, the overwhelmingly negative effect
of epinephrine reported by Dumas et al. (1) is not
supported by this randomized control trial of
epinephrine in humans.
Thus, a key question is whether any vasopressor
agent administered in the circulatory phase of
resuscitation will result in improved survival. Future
human investigation of vasopressor agents for OHCA,
whether prospective or retrospective, must separate
time courses for vasopressor administration.
EPINEPHRINE IS NOT THE
IDEAL VASOPRESSOR
The key question is whether epinephrine is the
optimal vasopressor. Over the past half-century,
resuscitation research in animals found that during
the circulatory phase (after 10 min) of untreated VF
arrest, survival was better when the CPP produced
by chest compressions was enhanced by a variety
of vasopressors (pure alpha-adrenergic drugs such
as phenylephrine or methoxamine, alpha- and
beta-adrenergic agonists such as epinephrine, and
epinephrine given with a beta-adrenergic blocker)
(9–11). It has been shown that during the circulatory
phase of VF arrest, resuscitation was effective
with epinephrine plus a beta-adrenergic blocker butnot with epinephrine plus an alpha-adrenergic
blocker (10).
Further research, ﬁrst in animal models and later
in humans, can continue to assess whether a pure
alpha agent or combination of agents may be superior
to epinephrine during the circulatory phase of
resuscitation.
LIMITATIONS AND CONTRIBUTIONS
There are 3 limitations to the study by Dumas et al.
(1) that readily come to mind. The ﬁrst is that it is
not known why about one-fourth of the patients
were not given epinephrine. The second is that
those receiving epinephrine had less favorable
prognostic characteristics; they were older, less
likely to have a witnessed event, and less likely to
present with a shockable rhythm, and they had
a longer duration of resuscitation (p < 0.001).
Third, the survival rates of emergency medical
services that followed guideline recommenda-
tions for early treatment with epinephrine and
had short response times reported excellent sur-
vival rates of patients with OHCA secondary to VF
arrest (12).
Nevertheless, Dumas et al. (1) have made a major
contribution to resuscitation science for at least 2
reasons. First, their work adds to the concern that
epinephrine is not the ideal vasopressor during
resuscitation of patients with OHCA. Second, they
found that the adverse effects associated with late
and repeated doses of epinephrine were not modi-
ﬁed by post-resuscitation care such as hypothermia.
This ﬁnding is disappointing but requires further
investigation, for example, to determine if longer
durations of hypothermia might be necessary in this
or other subgroup of patients with ROSC after
OHCA.
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